🇺🇸 FDA
Patent

US 10940214

Neuronal specific targeting of caveolin expression to restore synaptic signaling and improve cognitive function in the neurodegenerative brain and motor function in spinal cord

granted A61KA61K31/7088A61K38/17

Quick answer

US patent 10940214 (Neuronal specific targeting of caveolin expression to restore synaptic signaling and improve cognitive function in the neurodegenerative brain and motor function in spinal cord) held by The Regents of the University of California expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K31/7088, A61K38/17, A61K38/177, A61K48/00